Radiopharm says interim Phase 2b RAD101 PET trial meets primary endpoint with 93% MRI concordance

PUBT · 4d ago
Radiopharm says interim Phase 2b RAD101 PET trial meets primary endpoint with 93% MRI concordance
  • Radiopharm Theranostics flagged positive interim Phase 2b imaging data for RAD101 in suspected recurrent brain metastases.
  • Results were previously disclosed; updated findings are slated for a late-breaking oral presentation at the Society of Neuro-Oncology meeting on Nov. 12-15, 2026.
  • The interim readout supported RAD101’s ability to help distinguish active disease from treatment-related changes, a key clinical decision point.
  • The data are intended to underpin a global Phase 3 imaging trial; an FDA meeting is set for Oct. 1 to align on the protocol.
  • Management highlighted a roughly $600 million U.S. brain-metastases imaging market with no approved PET products.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140800PRIMZONEFULLFEED1001262476) on September 14, 2026, and is solely responsible for the information contained therein.